Small-molecule control of CAR T cells.

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Chimeric antigen receptor (CAR) T cell therapy offers a revolutionary approach to treating cancer by genetically modifying patient T cells.
• Despite significant successes in curing some late-stage cancers, CAR T cell therapy faces challenges including toxicity, limited cell survival, and therapeutic resistance.

Purpose of the Study:

• To review and categorize small-molecule-based control systems designed to overcome limitations in CAR T cell therapy.
• To detail the molecular mechanisms of these control systems and highlight their clinical applications and future potential.

Main Methods:

• Categorization of small-molecule controllers based on their functional roles in modulating CAR T cell activity.
• Detailed explanation of the molecular mechanisms underlying various small-molecule control strategies.
• Review of existing clinical applications and emerging research in the field.

Main Results:

• Small-molecule control systems can mitigate CAR T cell toxicities by enabling elimination or functional switching of engineered cells.
• These systems can enhance therapeutic efficacy through direct antigen targeting or pro-drug activation for broader cancer cell killing.
• Examples of small-molecule controllers include protease inhibitors, protein dimerizers, protein degraders, bi-specific adaptors, and conditionally activated chemotherapeutics.

Conclusions:

• Small-molecule control systems represent a critical advancement in refining CAR T cell therapy.
• These systems offer versatile strategies to enhance safety, improve persistence, and broaden the applicability of CAR T cell therapies in oncology.
• Further development and clinical translation of these control mechanisms hold significant promise for improving patient outcomes in cancer treatment.